Phathom Pharmaceuticals PHAT Q1 2026 Disappoints EPS 037 Below 033 Views Hims Hers Health Reports First Quarter 2026 Results Highlighting Momentum in Telehealth Platform USMCA Continues to Shape North American Auto Manufacturing as 2026 Review Looms PennyMac PMTU Stalls at 2550 Consolidation Phase 20260514 Jeff Bezos Suggests Aggressive Timeline for Space Data Centers May Be Overly Optimistic What Quoin QNRXs 445 Decline Means for Investors 20260520 Anthropic Targets 109 Billion in Q2 Revenue Potentially Marking First Profitable Quarter Source Says FrontView REIT FVR Falls 096 Watching 1665 Support 20260521 Indias Satirical Cockroach Party Claims Website Blocked Highlighting Digital Censorship Concerns SP 500 Reaches Record Close on AI Enthusiasm Micron Market Cap Hits 1 Trillion Sindhu Trade Links Surges After Announcing Acquisitions and Capital Hike JPMorgan Adjusts HPQ Price Target Ahead of Upcoming Earnings Report ADP Private Payrolls Rise 109000 in April Surpassing Expectations Signaling Labor Market Resilience Oil Prices Edge Higher Amid Stalled Progress in USIran Nuclear Negotiations ARTNA Q3 2025 Earnings Narrow EPS Beat Signals Steady Operations Amid Utility Sector Stability IMRX Q1 2026 Earnings Narrower Loss Exceeds Expectations as Pipeline Progress Continues Texas Capital Bancshares Series B TCBIO Q1 2026 Earnings EPS Exceeds Estimates as Preferred Stock Holds Steady Emera Q1 2026 Earnings EPS Surges 1846 Above Estimates Shares Edge Higher MS Q1 2026 Earnings Earnings Beat by 1092 as EPS Surges to 343 THO Q1 2026 Earnings Massive EPS Surprise of 831 Drives Stock Higher RPRX Q1 2026 Earnings EPS Beat Drives Positive Stock Movement Pioneer Power Solutions Inc PPSI Q1 2026 Earnings Loss Widens Stock Rises Unexpectedly KNDI Q2 2024 Earnings Modest Profit Amid Limited Disclosure HIG Q1 2026 Earnings EPS Misses Estimates Amid Elevated Catastrophe Losses EWBC Q1 2026 Earnings EPS Surpasses Estimates Amid Solid Operating Performance Trucking Fleets Face Accelerated Regulatory and AIDriven Transformation Industry Panel Warns Recursion Pharmaceuticals RXRX Q1 2026 Earnings Narrower Loss Surprises Market but Stock Dips on PreRevenue Status